Mohammed Al-Maadheed

Prof. Dr. Mohammed Al-Maadheed

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
MAMaryam Ali Al-Nesf
Maryam Ali Al-Nesf
HAHouari B. Abdesselem
Houari B. Abdesselem
IBIlham Bensmail
Ilham Bensmail
SIShahd Ibrahim
Shahd Ibrahim
WSWalaa A. H. Saeed
Walaa A. H. Saeed
FAFares Al-Ejeh
Fares Al-Ejeh
COVID-19 complications still present a huge burden on healthcare systems and warrant predictive risk models to triage patients and inform early intervention. Here, we profile 893 plasma proteins from 50 severe and 50 mild-moderate COVID-19 patients, and 50 healthy controls, and show that 375 proteins are differentially expressed in the plasma of severe COVID-19 patients. These differentially expressed plasma proteins are implicated in the pathogenesis of COVID-19 and present targets for candidate drugs to prevent or treat severe complications. Based on the plasma proteomics and clinical lab tests, we also report a 12-plasma protein signature and a model of seven routine clinical tests that validate in an independent cohort as early risk predictors of COVID-19 severity and patient survival. The risk predictors and candidate drugs described in our study can be used and developed for personalized management of SARS-CoV-2 infected patients.

28 April 2021 in Viruses
Verified
Journal Article
Open access
PDF file
MSMuneerah Smith
Muneerah Smith
HAHouari Abdesselem
Houari Abdesselem
MMMichelle Mullins
Michelle Mullins
TTTi-Myen Tan
Ti-Myen Tan
ANAndrew J. M. Nel
Andrew J. M. Nel
JBJonathan Blackburn
Jonathan Blackburn
The COVID-19 pandemic has affected all individuals across the globe in some way. Despite large numbers of reported seroprevalence studies, there remains a limited understanding of how the magnitude and epitope utilization of the humoral immune response to SARS-CoV-2 viral anti-gens varies within populations following natural infection. Here, we designed a quantitative, multi-epitope protein microarray comprising various nucleocapsid protein structural motifs, including two structural domains and three intrinsically disordered regions. Quantitative data from the microarray provided complete differentiation between cases and pre-pandemic controls (100% sensitivity and specificity) in a case-control cohort (n = 100). We then assessed the influence of disease severity, age, and ethnicity on the strength and breadth of the humoral response in a multi-ethnic cohort (n = 138). As expected, patients with severe disease showed significantly higher antibody titers and interestingly also had significantly broader epitope coverage. A significant increase in antibody titer and epitope coverage was observed with increasing age, in both mild and severe disease, which is promising for vaccine efficacy in older individuals. Additionally, we observed significant differences in the breadth and strength of the humoral immune response in relation to ethnicity, which may reflect differences in genetic and lifestyle factors. Furthermore, our data enabled localization of the immuno-dominant epitope to the C-terminal structural domain of the viral nucleocapsid protein in two independent cohorts. Overall, we have designed, validated, and tested an advanced serological assay that enables accurate quantitation of the humoral response post natural infection and that has revealed unexpected differences in the magnitude and epitope utilization within a population.

3 February 2024 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
MMMonica Mazzarino
Monica Mazzarino
HAHana Al-Mohammed
Hana Al-Mohammed
SASara Khalid Al-Darwish
Sara Khalid Al-Darwish
SSSofia Salama
Sofia Salama
AAAlAnoud Al-Kaabi
AlAnoud Al-Kaabi
MAMohammed Al-Maadheed
Mohammed Al-Maadheed

28 August 2021 in Drug Testing and Analysis
Verified
Journal Article
Open access
PDF file
SVS. C. Voss
S. C. Voss
MYMohamed Yassin
Mohamed Yassin
JGJ. C. Grivel
J. C. Grivel
SHS. Al Hmissi
S. Al Hmissi
NAN. Allahverdi
N. Allahverdi
MAMohammed Al-Maadheed
Mohammed Al-Maadheed
The purpose of this pilot study was to investigate the effects of the transfusion of one erythrocyte concentrate on the number of circulating Red Blood Cell Extracellular Vesicles (RBC-EVs) and their clearance time. Six, healthy volunteers donated their blood and were transfused with their Red Blood Cell concentrate after 35-36 days of storage. One K2EDTA and one serum sample were collected before donation, at four timepoints after donation and at another six timepoints after transfusion. RBC-EVs were analysed on a Cytek Aurora flow-cytometer. A highly significant increase (p<0.001) of RBC-EVs from an average of 60.1±19.8 (10^3/μL) at baseline to 179.3±84.7 (10^3/μL) in the first 1-3 hours after transfusion could be observed. Individual differences in the response to transfusion became apparent with one volunteer showing no increase and another an increased concentration at one timepoint after donation due to an influenza infection. We concluded that in an individualized passport approach increased RBC-EVs might be considered as additional evidence when interpreting suspicious ABPs but for this additional research related to sample collection and transport processes as well as method development and harmonization would be necessary.

3 June 2022 in Metabolites
Verified
Journal Article
Open access
PDF file
EUEhsan Ullah
Ehsan Ullah
Ayman El-MenyarAyman El-Menyar
Ayman El-Menyar
KKKhalid Kunji
Khalid Kunji
REReem Elsousy
Reem Elsousy
HMHaira R. B. Mokhtar
Haira R. B. Mokhtar
JSJassim Al Suwaidi
Jassim Al Suwaidi
Coronary heart disease (CHD) is a major cause of death in Middle Eastern (ME) populations, with current studies of the metabolic fingerprints of CHD lacking in diversity. Identification of specific biomarkers to uncover potential mechanisms for developing predictive models and targeted therapies for CHD is urgently needed for the least-studied ME populations. A case-control study was carried out in a cohort of 1001 CHD patients and 2999 controls. Untargeted metabolomics was used, generating 1159 metabolites. Univariate and pathway enrichment analyses were performed to understand functional changes in CHD. A metabolite risk score (MRS) was developed to assess the predictive performance of CHD using multivariate analysis and machine learning. A total of 511 metabolites were significantly different between the CHD patients and the controls (FDR p < 0.05). The enriched pathways (FDR p < 10−300) included D-arginine and D-ornithine metabolism, glycolysis, oxidation and degradation of branched chain fatty acids, and sphingolipid metabolism. MRS showed good discriminative power between the CHD cases and the controls (AUC = 0.99). In this first study in the Middle East, known and novel circulating metabolites and metabolic pathways associated with CHD were identified. A small panel of metabolites can efficiently discriminate CHD cases and controls and therefore can be used as a diagnostic/predictive tool.

23 March 2021 in Drug Testing and Analysis
Verified
Journal Article
Open access
PDF file
SKS Kraiem
S Kraiem
MAM Y Al-Jaber
M Y Al-Jaber
MAMohammed Al-Maadheed
Mohammed Al-Maadheed
AAA S Al-Menhali
A S Al-Menhali
NAN J AlThani
N J AlThani
MAM Almaadheed
M Almaadheed
Ecdysteroids are of interest as potential sport performance enhancers, due to their anabolic effects. The current study aimed to analyze levels of the most abundant ecdysteroid, ecdysterone (20‐hydroxyecdysone, 20‐OHE) in easily available dietary supplements, and, outline an analytical strategy for its detection, and that, of its metabolites, (1) following administration of pure 20‐OHE to uPA(+/+)‐SCID mice with humanized liver, (2) in a human volunteer after ingestion of two supplements, one with a relatively low, and the other a high, concentration of 20‐OHE, and, (3) to estimate the prevalence of use of 20‐OHE in elite athletes (n = 1000). Of the 16 supplements tested, only five showed detectable levels of 20‐OHE, with concentrations ranging from undetectable up to 2.3 mg per capsule. Urine of uPA(+/+)‐SCID urine showed the presence of 20‐OHE and its metabolite, 14 deoxy ecdysterone, within 24 hours (hr) of ingestion. In humans, both the parent and the metabolite were detectable within 2 to 5 hr of ingestion, with the metabolite being detectable for longer than the parent. After ingestion of a low dose supplement, the parent and metabolite were detectable for 70 and 48 hr, while following the higher dose it was 96 and 48 hr, respectively. Analysis of urines from athletes (n = 1000) confirmed four positives for 20‐OHE, suggesting a prevalence of use of 0.4%. Prevalence of its use by elite athletes was relatively low, however, this needs to be confirmed in other populations, and with other related ecdysteroids.